SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 31.09% in the sales to Rs. 7161.30 millions was observed for the quarter ended June 2022. The sales figure stood at Rs. 5463.00 millions during the year-ago period.The Net Profit of the company registered a slight decline of -12.16% to Rs. 1012.90  millions from Rs. 1153.10 millions.The Operating Profit of the company witnessed a decrease to 1684.90 millions from 1711.90 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 7161.30 5463.00 31.09 7161.30 5463.00 31.09 21898.76 18919.95 15.74
Other Income 5.10 128.80 -96.04 5.10 128.80 -96.04 386.14 1118.89 -65.49
PBIDT 1684.90 1711.90 -1.58 1684.90 1711.90 -1.58 5475.24 6682.54 -18.07
Interest 57.90 8.90 550.56 57.90 8.90 550.56 49.49 71.92 -31.19
PBDT 1627.00 1703.00 -4.46 1627.00 1703.00 -4.46 5425.75 6610.62 -17.92
Depreciation 256.90 174.80 46.97 256.90 174.80 46.97 712.82 673.55 5.83
PBT 1370.10 1528.20 -10.35 1370.10 1528.20 -10.35 4712.93 5937.07 -20.62
TAX 357.20 375.10 -4.77 357.20 375.10 -4.77 1102.91 1466.23 -24.78
Deferred Tax 117.20 -4.90 -2491.84 117.20 -4.90 -2491.84 -122.09 91.23 -233.83
PAT 1012.90 1153.10 -12.16 1012.90 1153.10 -12.16 3610.02 4470.84 -19.25
Equity 154.60 154.60 0.00 154.60 154.60 0.00 154.56 154.56 0.00
PBIDTM(%) 23.53 31.34 -24.92 23.53 31.34 -24.92 25.00 35.32 -29.21

JB Chem & Pharma Share Price

1997.35 22.65 (1.15%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×